Several other research firms have also recently issued reports on FIXX. Robert W. Baird assumed coverage on Homology Medicines in a research report on Monday, September 9th. They set an outperform rating and a $30.00 target price on the stock. Zacks Investment Research raised Homology Medicines from a sell rating to a hold rating in a research note on Tuesday, July 16th. Canaccord Genuity set a $37.00 price target on Homology Medicines and gave the stock a buy rating in a research note on Friday, July 26th. Finally, HC Wainwright set a $36.00 price target on Homology Medicines and gave the stock a buy rating in a research note on Tuesday, September 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $31.40.
NASDAQ FIXX opened at $13.74 on Friday. The business’s 50 day moving average is $17.65 and its two-hundred day moving average is $19.54. Homology Medicines has a 12-month low of $12.66 and a 12-month high of $31.80. The stock has a market capitalization of $572.44 million, a price-to-earnings ratio of -6.87 and a beta of 0.09.
Homology Medicines (NASDAQ:FIXX) last released its earnings results on Thursday, August 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.06). Homology Medicines had a negative return on equity of 38.74% and a negative net margin of 3,232.67%. The business had revenue of $0.39 million for the quarter, compared to analyst estimates of $1.00 million. As a group, research analysts predict that Homology Medicines will post -2.27 earnings per share for the current year.
In related news, CFO W Bradford Smith sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $17.39, for a total value of $104,340.00. Also, insider Albert Seymour sold 9,300 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $17.39, for a total value of $161,727.00. In the last ninety days, insiders sold 84,566 shares of company stock worth $1,510,800. 33.40% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of FIXX. BlackRock Inc. lifted its stake in shares of Homology Medicines by 48.7% during the 2nd quarter. BlackRock Inc. now owns 2,084,139 shares of the company’s stock worth $40,786,000 after purchasing an additional 682,665 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Homology Medicines by 1.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,006,682 shares of the company’s stock worth $38,748,000 after purchasing an additional 25,312 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Homology Medicines by 84.3% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,957,184 shares of the company’s stock worth $38,302,000 after purchasing an additional 894,960 shares during the period. Vanguard Group Inc. lifted its stake in shares of Homology Medicines by 53.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,016,124 shares of the company’s stock worth $19,886,000 after purchasing an additional 355,908 shares during the period. Finally, Rock Springs Capital Management LP lifted its stake in shares of Homology Medicines by 14.9% during the 2nd quarter. Rock Springs Capital Management LP now owns 425,000 shares of the company’s stock worth $8,317,000 after purchasing an additional 55,000 shares during the period. 68.09% of the stock is currently owned by hedge funds and other institutional investors.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Featured Story: Trading Options- What is a Strangle?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.